Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
5 hedge funds and large institutions have $20K invested in Northwest Biotherapeutics, Inc. Common stock in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
0% more capital invested
Capital invested by funds: $20K → $20K ($0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$5K |
Top Sellers
NWBO Hedge Fund Activity: Q1 2020 in Review
5 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2020, worth a combined $20K — unchanged from a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NWBO positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Moloney Securities Asset Management, opening a new position worth an estimated $5K.
- 5 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2020, up from 4 in Q4 2019.
- Funds reported $20K of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2020, unchanged quarter-over-quarter.
- 1 fund opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2020 and 0 closed out, a net change of +1 holder.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2020 was Moloney Securities Asset Management, an estimated $5K added.
Based on aggregated 13F filings for Q1 2020.